The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2022 Summer Meeting | Which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy?

Name: Which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy?
Uploaded: 2022-07-08T00:00:00Z
Duration: 1 min 27 s
Description: Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, discusses which subsets of patients with mesothelioma benefit from immunotherapy. This interview took place at the BTOG 2022 Summer Meeting congress in London.

Riyaz Shah • 8 Jul 2022

BTOG 2022 Summer Meeting

Lung Cancer Mesothelioma

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, discusses which subsets of patients with mesothelioma benefit from immunotherapy. This interview took place at the BTOG 2022 Summer Meeting congress in London.